# IDeate-PanTumor01 (NCT04145622)

> Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04145622
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Advanced Solid Tumor; Malignant Solid Tumor
- Interventions: Ifinatamab deruxtecan (I-DXd)
- Enrollment: 247
- Primary outcome: Evaluate the incidence of dose-limiting toxicities (DLTs)
- Primary outcome: Evaluate the incidence of adverse events (AEs)
- Primary outcome: Investigate the antitumor activity of ifinatamab deruxtecan (I-DXd)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ideate-pantumor01-nct04145622